Edward Gabrielson

Active 1985–2025

109
Papers
32,987
Citations
85
h-index
108
i10-index

Citations

Citations per year for Edward Gabrielson1971: 1 citations1985: 1 citations1986: 7 citations1987: 8 citations1988: 7 citations1989: 7 citations1990: 7 citations1991: 5 citations1992: 8 citations1993: 5 citations1994: 21 citations1995: 31 citations1996: 70 citations1997: 76 citations1998: 104 citations1999: 132 citations2000: 131 citations2001: 177 citations2002: 227 citations2003: 210 citations2004: 245 citations2005: 255 citations2006: 255 citations2007: 253 citations2008: 264 citations2009: 223 citations2010: 248 citations2011: 237 citations2012: 233 citations2013: 207 citations2014: 206 citations2015: 307 citations2016: 356 citations2017: 392 citations2018: 405 citations2019: 1,230 citations2020: 1,482 citations2021: 1,292 citations2022: 1,026 citations2023: 743 citations2024: 998 citations2025: 507 citations2026: 23 citations1972–1984: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 5,450 citing papers, 31.2% of this breakdownChina: 2,646 citing papers, 15.1% of this breakdownUnited Kingdom: 920 citing papers, 5.3% of this breakdownJapan: 771 citing papers, 4.4% of this breakdownGermany: 732 citing papers, 4.2% of this breakdownItaly: 624 citing papers, 3.6% of this breakdownCanada: 552 citing papers, 3.2% of this breakdownFrance: 515 citing papers, 3% of this breakdownSpain: 492 citing papers, 2.8% of this breakdownNetherlands: 390 citing papers, 2.2% of this breakdownAustralia: 380 citing papers, 2.2% of this breakdownSouth Korea: 357 citing papers, 2% of this breakdown
0%31.2%Other 20.8%

Fields

  • Biochemistry, Genetics and Molecular Biology48.7%
  • Medicine43.3%
  • Immunology and Microbiology3.4%
  • Engineering0.8%
  • Agricultural and Biological Sciences0.8%
  • Computer Science0.8%
  • Other2.2%

Topics

  • Cancer Immunotherapy and Biomarkers5.4%
  • Epigenetics and DNA Methylation5.3%
  • Lung Cancer Treatments and Mutations4.5%
  • Cancer Genomics and Diagnostics4.1%
  • RNA modifications and cancer3.8%
  • Cancer-related gene regulation2.4%
  • Other74.5%

Coauthors

All papers

Open in search
  1. Comprehensive molecular profiling of lung adenocarcinoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Rameen Beroukhim, Juok Cho, Daniel DiCara, David Heiman, Pei Lin, William Mallard, Douglas Voet, Hailei Zhang, Lihua Zou, Michael S. Noble, Nils Gehlenborg, Helga Thorvaldsdottir, Marc-Danie Nazaire, Jim Robinson, William Lee, Marc Ladanyi, Nikolaus Schultz, Ronglai Shen, William D. Travis, B. Arman Aksoy, Giovanni Ciriello, Gideon Dresdner, Jianjiong Gao, Benjamin Gross, Venkatraman E. Seshan, Boris Reva, Rileen Sinha, S. Onur Sumer, Nils Weinhold, Chris Sander, Natasha Rekhtman, Maureen Zakowski, Valerie W. Rusch, David G. Beer, Leslie Cope, Ludmila Danilova, James G. Herman, Stephen B. Baylin, Peter Illei, Edward Gabrielson, James Shin, Beverly Lee, Kristen Rodgers, Dante Trusty, Malcolm V. Brock, Chad J. Creighton, David Wheeler, Li Ding, Ramaswamy Govindan, Cyriac Kandoth, Robert Fulton, Lucinda L. Fulton, Michael D. McLellan, Richard K. Wilson, Kai Ye, Catrina C. Fronick, Christopher A. Maher, Christopher A. Miller, Michael C. Wendl, Christopher Cabanski, Elaine Mardis, Mark A. Watson, Sandra McDonald, Bryan Meyers, Raju Kucherlapati, Angela Hadjipanayis, Eran Hodis, Semin Lee, Angeliki Pantazi, Xiaojia Ren and 210 more - Nature 2014 cited by 5,918

  2. Neoadjuvant PD-1 Blockade in Resectable Lung Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Janis M. Taube, Victor E. Velculescu, Suzanne L. Topalian, Julie R. Brahmer, Drew M. Pardoll - New England Journal of Medicine 2018 cited by 2,135

  3. Small Molecule Inhibitor of NRF2 Selectively Intervenes Therapeutic Resistance in KEAP1-Deficient NSCLC Tumors

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - ACS Chemical Biology 2016 cited by 613

  4. Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Cancer Discovery 2016 cited by 899

  5. Collective Invasion in Breast Cancer Requires a Conserved Basal Epithelial Program

    Authors: , , , - Cell 2013 cited by 874

  6. Association between pathologic response and survival after neoadjuvant therapy in lung cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Nature Medicine 2023 cited by 162

  7. Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy

    Authors: , , , - Seminars in Cancer Biology 2017 cited by 830

  8. Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Rachel Karchin, Drew M. Pardoll, Jamie E. Chaft, Matthew D. Hellmann, Julie R. Brahmer, Victor E. Velculescu - Cancer Research 2018 cited by 314

  9. NRF2 Activation Promotes Aggressive Lung Cancer and Associates with Poor Clinical Outcomes

    Authors: , , , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2020 cited by 174

  10. Dysfunctional KEAP1–NRF2 Interaction in Non-Small-Cell Lung Cancer

    Authors: , , , , , , , , , , , - PLoS Medicine 2006 cited by 1,047

  11. Long Interspersed Element-1 Protein Expression Is a Hallmark of Many Human Cancers

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - American Journal Of Pathology 2014 cited by 371

  12. Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Stephen B. Baylin, Julie R. Brahmer, Robert B. Scharpf, Patrick M. Forde, Victor E. Velculescu - Nature Cancer 2020 cited by 207

  13. Prevalence of the Alternative Lengthening of Telomeres Telomere Maintenance Mechanism in Human Cancer Subtypes

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - American Journal Of Pathology 2011 cited by 520

  14. Chemotherapy induces enrichment of CD47 + /CD73 + /PDL1 + immune evasive triple-negative breast cancer cells

    Authors: , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2018 cited by 312

  15. Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Non–Small Cell Lung Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Kellie N. Smith - Clinical Cancer Research 2019 cited by 158

  16. Transcription factor NRF2 regulates miR-1 and miR-206 to drive tumorigenesis

    Authors: , , , , , , , , , , , , , , , - Journal of Clinical Investigation 2013 cited by 329

  17. Added Value of Computer-aided CT Image Features for Early Lung Cancer Diagnosis with Small Pulmonary Nodules: A Matched Case-Control Study

    Authors: , , , , , , , , , , , , , , , , - Radiology 2017 cited by 182

  18. Peptide-based PET quantifies target engagement of PD-L1 therapeutics

    Authors: , , , , , , , , , , , , , , , , , - Journal of Clinical Investigation 2018 cited by 141

  19. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers

    Authors: , , , , , , , - Nature Medicine 1995 cited by 1,990

  20. Hypoxia-inducible factors regulate pluripotency factor expression by ZNF217- and ALKBH5-mediated modulation of RNA methylation in breast cancer cells

    Authors: , , , , , , - Oncotarget 2016 cited by 268

  21. Uncovering the Role of N-Acetyl-Aspartyl-Glutamate as a Glutamate Reservoir in Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Cell Reports 2019 cited by 107

  22. Chronic Cigarette Smoke-Induced Epigenomic Changes Precede Sensitization of Bronchial Epithelial Cells to Single-Step Transformation by KRAS Mutations

    Authors: , , , , , , , , , , , - Cancer Cell 2017 cited by 194

  23. Gallium-68–labeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics

    Authors: , , , , , , , , , , - Clinical Cancer Research 2022 cited by 28

  24. Cathepsin D as a potential therapeutic target to enhance anticancer drug-induced apoptosis via RNF183-mediated destabilization of Bcl-xL in cancer cells

    Authors: , , , , , , , , , , , - Cell Death and Disease 2022 cited by 48